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the recent position paper of the European Academy of 
Dermatology and Venereology  [1] . The choice of a topical 
steroid should be tailored to each patient regarding its 
potency, the vehicle, and the affected skin areas, but the 
season, environment, and the patient’s preference should 
also be considered  [2] .
 The class III topical corticosteroid mometasone fu-
roate is characterized by high efficacy together with low 
systemic availability and is established in the topical 
treatment of a variety of corticosteroid responsive disor-
ders. It is licensed as a spray to treat allergic rhinitis or 
asthma and as a lotion, cream, or ointment for dermal 
application in inflammatory skin diseases. Its high effi-
cacy and rapid onset of action, together with a favorable 
risk benefit profile, make it one of the most widely used 
topical corticosteroids  [3] . In inflammatory skin disor-
ders, mometasone furoate has become a standard medi-
cation for topical treatment  [3–6] . 
 Besides the active ingredient, other excipients and 
properties of topical preparations, such as penetration 
enhancers, or its lipophilicity, contribute to the bioavail-
ability of the active ingredient and thus its overall thera-
peutic efficacy.
 For the appropriateness in everyday use, the cosmetic 
properties of a preparation must not be underestimated. 
Ease of application, spreadability, and rate of absorption 
strongly support the patients’ adherence to treatment and 
thus contribute considerably to the clinical outcome  [7] .
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 Abstract 
 This double-blind controlled phase II study was conducted 
to compare a newly developed formulation of mometasone 
furoate with a water content of 33% (Monovo  Cream) and 
with a smooth consistency versus the commercially available 
fatty cream of mometasone furoate (Ecural  Fettcreme) in 
terms of efficacy, cosmetic properties, and patients’ accep-
tance. In 20 patients with mild to moderate atopic eczema, 
the preparations were tested intraindividually in a random-
ized mode and in two comparable lesion areas. Both prepa-
rations were equally effective and well tolerated. Due to im-
proved cosmetic properties, the new formulation was pre-
ferred by the patients when asked for preferential use. 
Quality of life could be improved by treating with both prep-
arations. 
 
Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Despite a number of shortcomings, topical corticoste-
roids are a mainstay in the treatment of atopic eczema 
(AE) and remain the recommended first-line therapy in 
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 In this study, we present clinical data of a newly devel-
oped oil-in-water cream with 0.1% mometasone furoate 
and a water content of 33% (Monovo  Cream 1 , prepara-
tion 1). The developmental efforts had focused on the 
convenience of its texture, good spreadability, and rapid 
absorption to improve the patients’ comfort and satisfac-
tion while requiring a topical corticosteroid. A commer-
cially available preparation with 0.1% mometasone fu-
roate (Ecural  Fettcreme 2 , preparation 2) with a margin-
al water content below 5% served as comparator.
 The aim of this study was to demonstrate the clinical 
equivalence of both preparations in terms of efficacy and 
tolerability in mild to moderate AE, and to compare the 
convenience of the products, as reflected by the patients’ 
assessment. Patients’ acceptance and overall satisfaction 
were quantified by means of two questionnaires, one re-
flecting the cosmetic properties of the products and the 
other skin-related quality of life (Dermatology Life Qual-
ity Index, DLQI).
 Patients, Materials and Methods 
 The single-center phase II study was performed in a random-
ized, double-blind, controlled design. Evaluation of efficacy was 
based on an intraindividual comparison in two predefined, com-
parable test areas.
 Overall, 20 male and female patients aged  6 18 years were in-
cluded. The major inclusion criterion was the presence of mild to 
moderate AE with at least two comparable lesional areas on oppo-
site extremities (forearm or lower leg). The clinical condition of 
mild to moderate AE had been defined as a scoring of AE (SCO-
RAD) of  6 5, with an erythema score of  6 2, and lichenification, 
dryness, and itching score of  6 1 each, and an Erlangen Atopy score 
sum not less than 10 points. The difference in local score values in 
the treatment fields was not allowed to exceed the level of 3.
 Patients who were eligible for study participation were re-
quired not to show any relevant findings suggestive of a concom-
itant disease. Female participants of childbearing age had to agree 
to use reliable contraception.
 A written informed consent was obtained from all partici-
pants. The study was conducted in accordance with German 
Drug Law (Arzneimittelgesetz), the currently valid revision of the 
Helsinki Declaration, and the International Conference on Har-
monisation Good Clinical Practice Guidelines (EudraCT-No. 
2009-017407-28; NCT 01119313).
 The treatment area was defined as the entire ventral forearm 
in case of lesions on the arm, or as the entire ventral lower leg in 
case of lesions on the leg. At least one lesional region within each 
of these areas had to cover  6 20 cm 2 . Areas between 100 and 300 
cm 2 per patient were subject to evaluation.
 Each predefined area was treated with 2 mg/cm 2 mometasone 
furoate, corresponding to an amount of 200–600   l of one of the 
test products (preparation 1 and preparation 2). The creams were 
applied once daily by the patients themselves at home; the treat-
ment period was 2 weeks.
 Adequate application was verified by weighing the returned 
amount of the product and by the records in a treatment diary. If 
a significant deviation from the estimated need was suspected at 
the visit on day 8, the patient was advised to adjust the dose.
 The patients were instructed to avoid activities causing exces-
sive sweating, such as sunbathing, or visiting public swimming 
pools during the study period. Patients were not allowed to use 
additives such as bath or shower oils, or any cosmetic prepara-
tions, in the test areas.
 The preparations were blinded and randomization was made 
by permutation of the treatment codes A and B. A permutation 
was randomly assigned to every patient, so that the treatments 
were randomly assigned to the treatment areas.
 Visits to the study site took place on day 1 (baseline), 8, and 15; 
the test areas were assessed prior to the application of each day’s 
dose. A total clinical assessment score was determined for every 
patient, treatment, and visit as the sum of the individual severity 
of clinical symptoms of the SCORAD: erythema, edema/papula-
tion, oozing/crusts, excoriations, lichenification, dryness, and 
itching. The severity of lesions was scored on a 4-point scale from 
0 (= no symptoms) to 3 (= severe symptoms).
 Corneometry was performed to quantify the stratum corne-
um hydration as a further measure of the treatment efficacy. At 
each visit, hydration was assessed perilesionally within each treat-
ment area in a predefined and marked treatment area with a Cor-
neometer CM 825 (Courage and Khazaka electronic, Cologne, 
Germany).
 The assessment of stratum corneum hydration by corneome-
try was evaluated descriptively by treatment and visit, providing 
descriptive statistics for the absolute values, for the changes from 
baseline, and for differences in changes from baseline between the 
two treatments. In addition to the standard descriptive statistics, 
the 95% confidence intervals of the mean are provided.
 The rate of efficient skin penetration, as a relevant cosmetic 
property, was estimated following the patients’ recorded answers 
to the question ‘has the test product been absorbed enough so that 
you would put on clothes again?’, asked 15, 30, 45, and 60 min af-
ter the first application (study day 1).
 Patients’ satisfaction was assessed by a questionnaire on cos-
metic properties and patients’ satisfaction, which the participants 
completed at baseline and at the end of treatment. The rating was 
done on a 5-point scale (completely applicable, extensively appli-
cable, somehow applicable, less applicable, and not applicable).
 Health-related quality of life was recorded using the DLQI.
 The overall assessment of the test preparations was based on 
the clinical evaluation (SCORAD), the stratum corneum hydra-
tion, the patients’ statements on skin penetration, and the answers 
in the questionnaires on cosmetic properties and on quality of life.
 Safety was evaluated on the basis of medical history and phys-
ical examination. Vital signs (blood pressure and pulse rate) were 
assessed on day 1 and on the last study day. Adverse events were 
recorded according to the physicians’ observations and the pa-
tients’ reports.
 1   Scheduled brand name Monovo Cream, Almirall Hermal GmbH, Ger-
many.
 2  Ecural Fettcreme (international trade name Elocon  ), Schering-Plough 
(Merck Sharp and Dohme Ltd.). 
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 Data Analysis and Statistics 
 Since the data were analyzed exploratively and interpreted in 
a non-confirmatory mode, no formal hypothesis had been postu-
lated. Evaluation of trends and identification of differences in ef-
ficacy were made by means of descriptive statistics. Statistical 
evaluation was made using the SAS software package. Analyses of 
the intent-to-treat (ITT) population and of the per protocol (PP) 
population are provided for efficacy parameters (local SCORAD 
and corneometry). The analysis of the cosmetic assessment and 
DLQI was limited to the PP population. The total clinical assess-
ment was determined as the sum of the individual clinical symp-
tom score (total symptom score, TSS) of the SCORAD intensity 
scale. Results are given as mean values  8 SD.
 Comparisons between treatments were performed applying 
the sign test as distribution free and robust procedure.
 Outcomes of the 10 questions of the questionnaire on quality 
of life (DLQI) surveyed on day 1 (baseline) and 15 (end of study) 
are presented by frequency tables (appendix 1) as the sum of the 
10 scores. Descriptive statistics are provided for the DLQI and the 
derived item-specific scores for both visits, as well as for their 
changes from baseline.
 Results 
 Baseline Data 
 Twenty patients with mild to moderate AE, 10 males 
and 10 females, all Caucasians, were included and valid for 
analyses. All patients performed all treatments as planned 
and documented in their diaries. The number of patients 
was identical for the safety, ITT, and PP population.
 At baseline, the size of the treatment areas, the sever-
ity of lesions, skin hydration, and itching were compara-
ble for both treatments.
 At baseline, the defined test areas to be treated were 
comparable regarding
 • the mean size of the treatment areas (175.5 and 175.3 
cm 2 for preparation 1 and 2, respectively); 
 • the severity of lesions as evaluated by clinical assess-
ment (SCORAD intensity criteria) with generally 
moderate erythema, edema/papulation, lichenifica-
tion, dryness, and itching (median = 2, each), mild ex-
coriations (median = 1), rare oozing/crusts (median = 
0), and TSS (median = 10.5 and 11 for preparation 1 
and 2, respectively); 
 • skin hydration as assessed by corneometry (mean 12.9 
 8 5.76 and 13.1  8 4.54 for preparation 1 and 2, re-
spectively); 
 • itching assessed by the first question of the question-
naire (concerning ‘the cosmetic properties and pa-
tients’ satisfaction with the product’) showing moder-
ate itching in 60% of the patients (12 out of 20). 
 Efficacy 
 At the end of the study period, both treatments result-
ed in improvement of the skin condition, as measured by 
the TSS, the intensity of erythema, edema/papulation, 
dryness, itching score and skin hydration, and had ben-
eficial effects on the patients’ satisfaction.
 After the first week of treatment, the mean TSS de-
clined from 11.0  8 1.93 to 4.3  8 2.58 for preparation 1 
and from 10.4  8 1.79 to 3.6  8 2.39 for preparation 2 
(comparator). The second treatment week added further 
improvement with mean end-of-study TSS values of 2.6 
 8 1.76 for preparation 1 and 2.5  8 1.76 for preparation 
2. After the entire treatment period, mean TSS change 
from baseline was –8.4  8 1.82 in the lesion areas treated 
with preparation 1, the newly developed formulation, and 
–8.0  8 1.64 in the areas treated with preparation 2, the 
comparator. The median TSS change from baseline was 
–8.5 for preparation 1 and –8.0 for preparation 2 at day 
15. The results were identical for the ITT and the PP anal-
ysis.
 The statistical comparison did not reveal significant 
differences in the mean change from baseline of the TSS 
at day 8 and 15.
 All individual symptoms of the clinical score showed 
similar improvement, reflecting the reduction of the TSS. 
A slight difference between the treatments could be ob-
served in the reduction of erythema: after 2 weeks of 
treatment, more lesional areas treated with preparation 2 
than with preparation 1 were completely free of erythema 
(65%, n = 13, compared to 50%, n = 10). 
 The mean TSS, severity of individual symptoms, and 
the percentage of patients showing complete absence 
(score 0) of the respective symptom on day 15 are pre-
sented in  table 1 a, b.
 Corneometry 
 The corneometry results (arbitrary units) showed 
considerable increase in skin moisturization with both 
preparations. The improvement of skin hydration was 
most pronounced in the first week for both preparations, 
where the mean values increased for preparation 1 from 
12.9  8 5.79 to 22.7  8 7.91 and from 13.1  8 4.54 to 20.8 
 8 6.90 for preparation 2, but remained perceptible dur-
ing the next week of treatment ( table 2 ;  fig. 1 ). The statis-
tical comparison of the intraindividual outcomes did not 
show significant differences between the treatments 
comparing mean corneometric values at baseline with 
day 8 and 15.
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 Questionnaire Statements regarding Cosmetic 
Properties and Patients’ Satisfaction 
 The patients’ acceptance of and satisfaction with the 
two mometasone preparations (questionnaire, see appen-
dix 1) were generally good for both preparations as docu-
mented in the questionnaire. Significant differences fa-
voring the newly developed mometasone cream were 
found for the following questions ( table 3 ):
 – Judgment of daily application: the statement ‘the 
cream is convenient for daily application’ was consid-
ered as completely applicable by 70% (n = 14) of judg-
ments for preparation 1 and 40% (n = 8) for prepara-
tion 2 (p = 0.0391). 
 – Time of permeation: rapid permeation was attributed 
to preparation 1 by 10 out of 20 and to preparation 2 
by 2 out of 20 patients (50 vs. 10%, p = 0.0063). 
 – Individual preference: 15 out of 20 patients preferred 
the newly developed cream (preparation 1) over the 
comparator (preparation 2), and 5 out of 20 did not (75 
vs. 25%, p = 0.0414). 
 A difference that was near statistical significance was 
found for ease and convenience of application and for the 
spreadability of the preparation:
 – The statement ‘the application of the cream is easy and 
convenient’ was tagged as completely applicable by 18 
out of 20 judgments on preparation 1 and by 13 out of 
20 for preparation 2 (90 vs. 65%, p = 0.0625). 
 – The statement ‘the cream is easy to spread’ was rated 
completely applicable by 12 out of 20 patients for prep-
aration 1 and by 4 out of 20 patients for preparation 2 
(60 vs. 20%, p = 0.0574). 
 All other questions or statements produced compara-
ble rating profiles.
Table 1. Severity of symptoms at baseline and after 1 and 2 weeks of treatment
a With preparation 1
Preparation 1
baseline day 8 day 15 day 15 score 0
Erythema 2.280.37 0.880.72 0.680.60 50 (n = 10)
Edema/papulation 1.780.57 0.680.60 0.380.55 80 (n = 16)
Oozing/crusts 0.280.37 0.0 0.0 100 (n = 20)
Excoriations 1.580.51 0.380.44 0.0 100 (n = 20)
Lichenification 1.980.72 1.680.76 1.380.64 10 (n = 2)
Dryness 1.880.77 0.980.59 0.480.60 65 (n = 13)
Itching 1.880.77 0.480.49 0.180.31 90 (n = 18)
TTS 11.081.93 4.382.58 2.681.76
TTS reduction from baseline –6.782.21 –8.481.82
b With preparation 2
P reparation 2, comparator
baseline day 8 day 15 day 15 score 0
Erythema 2.180.31 0.680.68 0.480.60 65 (n = 13)
Edema/papulation 1.680.60 0.580.69 0.380.57 75 (n = 15)
Oozing/crusts 0.180.22 0.0 0.0 100 (n = 20)
Excoriations 1.580.51 0.180.31 0.0 100 (n = 20)
Lichenification 1.980.64 1.480.82 1.380.64 10 (n = 2)
Dryness 1.880.70 0.880.55 0.580.60 60 (n = 12)
Itching 1.680.60 0.380.44 0.180.22 95 (n = 19)
TTS 10.481.79 3.682.39 2.581.76
TTS reduction from baseline –6.981.87 –8.081.64
Sco re 0 represents complete absence of the respective symptom in percentage (number of patients).
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Table 3. S tatements revealing superiority of the newly developed mometasone cream (preparation 1)
Statement (completely applicable) Preparation 1 Preparation 2 p value
The application of the cream is easy and convenient 90 (n = 18) 65 (n = 13) 0.0625
The cream is convenient for daily application 70 (n = 14) 40 (n = 8) 0.0391
The cream permeates quickly 50 (n = 10) 10 (n = 2) 0.0063
The cream is easy to spread 60 (n = 12) 20 (n = 4) 0.0574
I prefer the cream 75 (n = 15) 25 (n = 5) 0.0414
D ata are expressed as percentage (number of patients).
Table 2.  Results of corneometry after 1 and 2 weeks of treatment with preparations 1 and 2
Preparation 1 P reparation 2
baseline day 8 day 15 baseline day 8 day 15
Corneometry
Mean 12.985.79 22.787.91 25.887.29 13.184.54 20.886.90 24.088.34
Median 11.4 21.3 24.3 14.1 21.8 22.0
Mean change from baseline +9.985.38 +12.985.81 +7.785.17 +10.986.56
Val ues are arbitrary units.
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 Fig. 1. Improvement of skin hydration measured by corneometry (median) after 1 and 2 weeks of treatment with 
preparations 1 and 2. 
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 Skin Penetration 
 Preparation 1 was rated as sufficiently absorbed at the 
following time points: 15 min after application by 2 of 20 
patients (10.0%), 30 min after application in half of the 
patients (50%), and 45 and 60 min after application in 4 
patients (20%). The respective results for preparation 2 
are: 15 min after application in 4 patients (20.0%), 30 min 
after application in 3 patients (15.0%), 45 min after appli-
cation in 8 patients (40.0%), and 60 min after application 
in 5 patients (25.0%). Thirty minutes after application, 
60% (n = 12) of patients treated with preparation 1 rated 
penetration to be sufficient to put clothes on compared to 
35% of patients (n = 7) treated with preparation 2 (PP 
analysis). With a p value of 0.0625, the difference missed 
significance, but indicated a tendency.
 Improvement of Quality of Life 
 The data derived from the questionnaire on quality of 
life (DLQI, appendix 2) indicate considerable improve-
ment in patients’ quality of life during the study period. 
The mean index decreased from 8.5  8 5.2 at baseline to 
3.0  8 3.3 at day 15 (corresponding median values 7.0 and 
2.0, respectively), showing that the initially moderate im-
pact of the dermatological condition was reduced to a 
lower degree (median change from baseline –3.5).
 Six subscores of the DLQI, regarding symptoms and 
feelings (questions 1 and 2), daily activities (questions 3 
and 4), leisure (questions 5 and 6), work and school (ques-
tion 7), personal relationships (questions 8 and 9), and 
treatment (question 10), had been evaluated separately 
and showed improvement during the study period as 
clearly as the total index did.
 The improvement of symptoms and feelings showed a 
median decrease of 2.0 score points from baseline. Symp-
toms like itching, sore, pain, or stinging were absent in 
50% of the patients (n = 10) and were assessed as mild by 
most of the remaining patients. In 65% of the patients 
(n = 13), no embarrassment or compromised self-con-
sciousness due to the skin condition was noted at the end 
of the study period. The majority of the patients (65.0%, 
n = 13) reported that their skin condition did not interfere 
with their everyday activities. No influence of skin on the 
choice of clothes was noted in the majority of patients 
(70.0%, n = 14). During the study period, a slight im-
provement was seen concerning leisure and social activi-
ties. The majority of patients declared that their skin did 
not affect any social or leisure (80.0%, n = 15) or sports 
activities (65.0%, n = 13). A slight improvement was also 
observed regarding the attendance of work and school 
during the study period. All 20 patients reported that 
their skin condition did not prevent them from working 
or studying, and most of the patients (75.0%, n = 15) 
found that their skin had not been a problem at work or 
while studying. No relevant changes were noted in per-
sonal relationships. The majority of patients (85.0%, n = 
17) reported no problems with their partners or any of 
their close friends or relatives due to their skin and most 
of the patients (70.0%, n = 14) noted no sexual difficulties 
caused by their skin. Most of the patients (75.0%, n = 15) 
did not report any problems with the treatment of their 
skin. For detailed outcomes of the DLQI, see appendix 2.
 Safety 
 There were no adverse events reported in this trial. 
The final physical examination did not show abnormal 
findings in any of the patients. The investigators had 
considered all vital signs in an acceptable range. Slight 
changes in systolic and diastolic blood pressure and 
heart rate between baseline and final visit were clinically 
not relevant. Overall, this trial did not raise any safety 
concerns.
 Discussion 
 The development of new corticosteroids and respec-
tive formulations for topical application from the late 
1980s until today has targeted a better benefit/risk ratio. 
Mometasone furoate, one of these new derivatives  [8] , is 
characterized by persistent high intradermal concentra-
tions and very low systemic availability  [3] . Mometasone 
furoate is categorized as a class III topical corticosteroid, 
and its atrophogenic potential was found to be low  [6, 9] . 
Consequently, a therapeutic index of 2.0 has been attrib-
uted to this glucocorticoid  [3] .
 The overall treatment success does not only depend on 
the risk-benefit profile of the active ingredient. It may be 
supported or compromised by factors beyond the estab-
lished substance profile. Because excipients such as pen-
etration enhancers may add to efficacy and tolerability 
 [10] , two glucocorticoid preparations with the same ac-
tive ingredient are not necessarily interchangeable. 
Therefore, any new formulation requires the confirma-
tion of its clinical equivalence to the originator prepara-
tion prior to its approval as a medicinal product, even if 
its active ingredient is well established and approved as a 
therapeutic agent in other topical preparations.
 Another aspect of the formulation refers to the cos-
metic properties and the ease of use: the regularity of ap-
plication is crucial for patients suffering from chronic 
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skin conditions such as AE, and the patients’ adherence 
to treatment is better if a convenient and user-friendly 
preparation with good properties to spread and rapid 
penetration is provided. A medicinal product that is not 
accepted for cosmetic reasons tends to compromise the 
treatment adherence and treatment success.
 Ointments are sometimes considered to be of higher 
potency than creams containing the same concentration 
of the active ingredient, probably due to their occlusive 
effect which is supposed to enhance drug penetration by 
increasing hydration of the stratum corneum  [2, 11] . 
Contradictory findings have been published by Korting 
et al.  [12]  in 2005, suggesting similar efficacy for cream 
and ointment when the content of the respective gluco-
corticoid is the same.
 The therapeutic equivalence of the new mometasone 
formulation and the commercially available product has 
been described earlier on the basis of a vasoconstriction 
test and a psoriasis plaque test  [13] .
 In the study reported here, the equivalence of the new-
ly developed cream with a higher water content in an 
O/W emulsion with a well-established fatty cream used 
in AE patients could be confirmed. Its good moisturizing 
effect was not only shown by corneometry results, but is 
consistent with the improvement in skin dryness. In 65% 
(n = 13) of lesion areas treated by the new formulation 
(preparation 1) and 60% (n = 12) of lesion areas treated by 
preparation 2 (comparator) the symptom dryness was 
completely absent (score 0) at the end of study. These re-
sults might challenge the assumption of a superior mois-
turizing effect of an ointment and support the priority of 
the convenience of use.
 Conclusion 
 In terms of efficacy – assessed by the SCORAD score, 
the patients’ evaluation of the skin condition, and corne-
ometry measurements – the study data show that the new-
ly developed mometasone cream formulation with a water 
content of 33% is equivalent to the commercially available 
fatty cream with the same content of 0.1% mometasone 
furoate in the treatment of AE. These results also confirm 
the bioequivalence of both mometasone furoate prepara-
tions shown earlier in clinical experimental settings  [13] .
 The patient-reported acceptance of the new cream 
confirms the role of cosmetic properties and the impor-
tance of the ease of daily use of a topical preparation for 
the quality of life in patients with chronic skin disor-
ders.
 Appendix 
 Appendix 1 
 Questionnaire regarding cosmetic properties and patients’ 
satisfaction with the product:
 Part 1: Questions with answering options: completely appli-
cable, widely applicable, somehow applicable, less applicable, and 
not applicable:
 – The application of the cream is easy and convenient. 
 – The cream is convenient for daily application. 
 – The cream permeates quickly. 
 – The cream is well spreadable. 
 – The cream is suitable for the application on inflamed and sen-
sitive skin. 
 – I like the application of this cream more than the treatment I 
used before. 
 Appendix 2 
Questionnaire on quality of life (DLQI): 
Part 2
Question Answering options
Visible effect yes/no
The first effect was visible after ? treatment days
How has your skin condition im-
proved?
completely/visibly/slightly/
no difference/worse
How do you assess the tolerability 
of the creams?
very good/good/satisfying/
sufficient/poor
How do you assess the itching
of your skin after repeated
application?
severe/strong/moderate/
slight/no itching
I prefer cream
(Please tick only one cream)
A or B
I would recommend the cream to 
other patients
yes/no
Day 1
%
Day 15 
%
Over the last week, how itchy, 
sore, painful or stinging has your 
skin been?
Very much 25.0 0.0
A lot 65.0 10.0
A little 10.0 40.0
Not at all 0.0 50.0
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Day 1
%
Day 15 
%
Over the last week, how 
embarrassed or self-conscious 
have you been because of your 
skin?
Very much 5.0 0.0
A lot 15.0 0.0
A little 70.0 35.0
Not at all 10.0 65.0
Over the last week, how much has 
your skin interfered with you 
going shopping or looking after 
your home or garden?
Very much 0.0 0.0
A lot 10.0 0.0
A little 40.0 35.0
Not at all 50.0 65.0
Not relevant 0.0 0.0
Over the last week, how much has 
your skin influenced the clothes 
you wear?
Very much 20.0 5.0
A lot 5.0 10.0
A little 40.0 10.0
Not at all 35.0 70.0
Not relevant 0.0 5.0
Over the last week, how much has 
your skin affected any social or 
leisure activities?
Very much 10.0 0.0
A lot 5.0 0.0
A little 30.0 15.0
Not at all 55.0 80.0
Not relevant 0.0 5.0
Over the last week, how much has 
your skin made it difficult for you 
to do any sport?
Very much 10.0 5.0
A lot 0.0 0.0
A little 25.0 10.0
Not at all 50.0 65.0
Not relevant 15.0 20.0
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Day 1
%
Day 15 
%
Over the last week, has your skin 
prevented you from working or 
studying?
Yes 0.0 0.0
No 100.0 100.0
Not relevant 0.0 0.0
If ‘No’, over the last week, how 
much has your skin been a 
problem at work or studying?
A lot 15.0 0.0
A little 40.0 25.0
Not at all 45.0 75.0
Over the last week, how much has 
your skin created problems with 
your partner or any of your close 
friends or relatives?
Very much 5.0 0.0
A lot 5.0 0.0
A little 20.0 15.0
Not at all 70.0 85.0
Not relevant 0.0 0.0
Over the last week, how much has 
your skin caused any sexual 
difficulties?
Very much 0.0 0.0
A lot 15.0 0.0
A little 10.0 15.0
Not at all 60.0 70.0
Not relevant 15.0 15.0
Over the last week, how much of 
a problem has the treatment of
your skin been, for example by
Very much 5.0 0.0
A lot 5.0 0.0
A little 45.0 25.0
making your home messy or by
taking up time?
Not at all 35.0 75.0
Not relevant 10.0 0.0
